Researchers in The Lancet highlight coronary arterial inflammation’s role in increasing major adverse cardiac events and cardiovascular deaths, irrespective of coronary artery disease presence.
Risk-benefit determinations: FDA finalizes long-awaited guidance for drugmakers
The FDA on Thursday finalized guidance from September 2021 on the agency’s benefit-risk assessments for new drugs and biologics, spelling out its most pertinent considerations
October 20, 2023